Extension of the RENACER Study: 12-Month Efficacy, Safety and Certolizumab PEGol Survival in 501 Rheumatoid Arthritis Patients Vicenç Torrente-Segarra, Manuel Fernández Prada, Rosa Expósito, Noemí Patricia Garrido Puñal, Amalia Sánchez-Andrade, José Ramón Lamúa-Riazuelo, Alejandro Olivé, Juan Víctor Tovar

Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure Francisco J. Blanco, Esteban Rubio-Romero, Raimon Sanmartí, César Díaz-Torné, Pablo Talavera, Jochen Dunkel, Esperanza Naredo

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies Sebastião Cezar Radominski, Mario Humberto Cardiel, Gustavo Citera, Annelise Goecke, Juan Jose Jaller, Andrea Barranjard Vannucci Lomonte, Pedro Miranda, Patricia Velez, Daniel Xibillé, Kenneth Kwok, Ricardo Rojo, Erika Gabriela García